TCR2 Therapeutics Inc. Common Stock
TCRR
TCRR was delisted on the 31st of May, 2023.
118 hedge funds and large institutions have $1.07B invested in TCR2 Therapeutics Inc. Common Stock in 2020 Q4 according to their latest regulatory filings, with 44 funds opening new positions, 42 increasing their positions, 18 reducing their positions, and 8 closing their positions.
450% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 8
133% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 18
97% more capital invested
Capital invested by funds: $544M → $1.07B (+$526M)
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
44% more funds holding
Funds holding: 82 → 118 (+36)
6% more call options, than puts
Call options by funds: $3.79M | Put options by funds: $3.59M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$44.6M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$26.8M |
| 3 |
RCAMU
Rothschild & Co Asset Management US
Stamford,
Connecticut
|
+$17.4M |
| 4 |
State Street
Boston,
Massachusetts
|
+$15.7M |
| 5 |
BlackRock
New York
|
+$12.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$24.4M |
| 2 |
CCM
Consonance Capital Management
New York
|
-$23.4M |
| 3 |
Millennium Management
New York
|
-$4.45M |
| 4 |
GH
GAM Holding
Zurich,
Switzerland
|
-$3.38M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$2.53M |
TCRR Hedge Fund Activity: Q4 2020 in Review
118 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in TCR2 Therapeutics Inc. Common Stock (TCRR) for Q4 2020, worth a combined $1.07B — up 97% from $544M a quarter earlier.
Buyers outnumbered sellers: 44 funds opened new TCRR positions and 8 closed out — a net gain of 36 holders — while 42 added to existing stakes and 18 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $44.6M. The largest seller was Deerfield Management, exiting entirely with an estimated $24.4M sold.
- 118 institutional investors held TCR2 Therapeutics Inc. Common Stock (TCRR) as of Q4 2020, up from 82 in Q3 2020.
- Funds reported $1.07B of TCR2 Therapeutics Inc. Common Stock stock for Q4 2020, up 97% quarter-over-quarter.
- 44 funds opened new TCR2 Therapeutics Inc. Common Stock positions in Q4 2020 and 8 closed out, a net change of +36 holders.
- The largest TCR2 Therapeutics Inc. Common Stock buyer in Q4 2020 was Wellington Management Group, an estimated $44.6M added.
- The largest TCR2 Therapeutics Inc. Common Stock seller in Q4 2020 was Deerfield Management, an estimated $24.4M sold.
Based on aggregated 13F filings for Q4 2020.